文献速递贫血与红细胞疾病

重型β地中海贫血患者50年随访大型队列的总生存与无并发症生存

Overall and complication-free survival in a large cohort of patients with β-thalassemia major followed over 50 years.
PubMed 文献 · Am J Hematol · 2023-01-01

意大利七个中心对1970至1997年出生、随访至2020年的709例输血依赖型重型β地中海贫血患者进行纵向队列分析。30年总生存概率在最老出生队列为83.6%,最年轻队列为93.3%,女性生存优于男性;480例(67.7%)发生至少一种并发症,年轻队列无并发症生存更好。

要点

  • 30年总生存概率最老出生队列(1970-1974)为83.6%,最年轻队列(1985-1997)为93.3%(p=0.073)。
  • 女性生存优于男性(p=0.022),480例(67.7%)患者发生至少一种并发症。
  • 多因素分析中死亡独立危险因素包括心脏病(HR 4.63)、血清铁蛋白>1000 ng/mL(HR 15.5)等。

核心结论

  • 在充分获得医疗资源、最佳实践分享、持续研究和中心间协作下,重型β地中海贫血患者生存持续改善。

研究设计与样本

  • 纵向队列研究,纳入1970至1997年出生、随访至2020年的709例输血依赖型重型β地中海贫血患者(51.1%为男性),来自意大利七个主要中心。

主要发现

  • 30年总生存概率最老出生队列(1970-1974)为83.6%(95%CI: 78.5-89.1),最年轻出生队列(1985-1997)为93.3%(95%CI: 88.6-98.3),p=0.073。
  • 女性生存优于男性(p=0.022)。
  • 共93例死亡,中位年龄23.2岁,最常见疾病相关死因为心脏病(n=53)、骨髓移植并发症(n=10)、感染(n=8)、肝病(n=4)、癌症(n=3)、血栓栓塞(n=2)和严重贫血(n=1)。
  • 自2000年起心脏病死亡数稳步下降,2010年后未观察到骨髓移植相关死亡;年轻出生队列中骨髓移植中位年龄逐渐降低(p<0.001)。
  • 480例(67.7%)患者发生至少一种并发症;年轻出生队列无并发症生存更好(p<0.001),两性间无并发症生存可比(p=0.230)。

关键数值与推荐

  • 多因素分析中死亡独立危险因素:心脏病(HR 4.63,95%CI: 1.78-12.1,p=0.002)、血清铁蛋白>1000 ng/mL(HR 15.5,95%CI: 3.52-68.2,p<0.001)、男性(HR 2.75,95%CI: 0.89-8.45,p=0.078)、脾切除(HR 6.97,95%CI: 0.90-54.0,p<0.063)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We report data on survival and complications for a longitudinal cohort of 709 transfusion-dependent β-thalassemia major patients (51.1% males) born between 1970 and 1997 and followed through 2020 at seven major centers in Italy. Overall survival probability at 30 years was 83.6% (95%CI: 78.5-89.1) in the oldest birth cohort (1970-1974) compared with 93.3% (95%CI: 88.6-98.3) in the youngest birth cohort (1985-1997) (p = 0.073). Females showed better survival than males (p = 0.022). There were a total of 93 deaths at a median age of 23.2 years with the most frequent disease-related causes being heart disease (n = 53), bone marrow transplant (BMT) complication (n = 10), infection (n = 8), liver disease (n = 4), cancer (n = 3), thromboembolism (n = 2) and severe anemia (n = 1). There was a steady decline in the number of deaths due to heart disease from the year 2000 onwards and no death from BMT was observed after the year 2010. A progressive decrease in the median age of BMT was observed in younger birth cohorts (p < 0.001). A total of 480 (67.7%) patients developed ≥1 complication. Patients in younger birth cohorts demonstrated better complication-free survival (p < 0.001) which was comparable between sexes (p = 0.230). Independent risk factors for death in multivariate analysis included heart disease (HR: 4.63, 95%CI: 1.78-12.1, p = 0.002), serum ferritin >1000 ng/mL (HR: 15.5, 95%CI: 3.52-68.2, p < 0.001), male sex (HR: 2.75, 95%CI: 0.89-8.45, p = 0.078), and splenectomy (HR: 6.97, 95%CI: 0.90-54.0, p < 0.063). Survival in patients with β-thalassemia major continues to improve with adequate access to care, best practice sharing, continued research, and collaboration between centers.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Forni GL, Gianesin B, Musallam KM, et al. Overall and complication-free survival in a large cohort of patients with β-thalassemia major followed over 50 years. Am J Hematol. 2023. PMID: 36588408. doi:10.1002/ajh.26798

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。